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eurysms and no clinical evidence of other vascular 
disease we found 11 (79%) with hyperhomo- 
cysteinaemia (homocysteine >14.25~tmol/1). To date 
we have found no significant difference in B12 and 
folate levels in these patients. Results for the methylene 
tetrahydrofolate reductase transition are awaited. Pre- 
vious studies have found hyperhomocysteinaemia in 
up to 39% of patients with vascular disease s but not 
in aneurysmal disease. In addition to the anecdotal 
reports and further references quoted in this case 
report, recent work has demonstrated the induction 
of a serine elastase by homocysteine l nding additional 
evidence to the putative role of homocysteine in an- 
eurysm formation. 4 
What seems surprising is that relatively modest 
increases in plasma homocysteine seem to be so sig- 
nificant, as demonstrated by a three-fold increase in 
myocardial infarction, s The problem remains not only 
in understanding how homocysteine causes vascular 
disease, but in its relevance. It is now almost 30 years 
since homocysteine was first implicated in vascular 
disease. Numerous studies have established it as a 
risk factor which is modifiable, yet despite the ease 
with which homocysteine l vels can be lowered by 
dietary supplementation, we have no long-term pro- 
spective data on the influence of homocysteine low- 
ering treatment on progression of vascular disease. 
Such a study would answer the question about the 
possibility of managing small aneurysms with vitamin 
supplementation. Furthermore, studies on the mech- 
anism of homocysteine induced vascular damage 
using a reproducible in vitro model are required to 
elucidate the role of homocysteine in atherogenesis. 
S. Caldwell  
Birmingham, U.K. 
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Rifampicin-Soaked Grafts 
Sir, 
We read with interest the article by Torsello and Sand- 
man regarding the use of antibiotic-bonded grafts in 
vascular graft infection. They show that the in situ 
technique using a rifampin-bonded graft can be an 
effective strategy with good mid-term results. After a 
mean follow-up of 33 months, only one recurrence 
and one death by sepsis was found among 12 patients 
treated with a gelatin-coated Dacron prosthesis soaked 
with rifampin (60mg/ml). Recent clinical and ex- 
perimental studies have suggested an expanded role 
for an antibiotic-bonded vascular prosthesis in the 
treatment of established graft infections, particularly 
when the graft is impregnated with gelatin or collagen, 
leading to drug accumulation and prolonged release. 
Despite the use of different concentrations of rifampin 
in which grafts have been immersed (ranging from 
lmg/ml  to 60mg/ml), this procedure has been as- 
sociated with excellent results in animal models 24 and 
in some sporadic linical cases. Until now 16 patients 
receiving antibiotic-bonded grafts for vascular in- 
fections have been reported3 -s Although the simplicity 
of this bonding technique greatly enhances its clinical 
applicability, our experience suggests that the use of 
in situ replacement of infected vascular prosthesis with 
rifampin-soaked vascular grafts does not avoid the 
risk of recurrent infections. 
Between 1993 and 1995, five patients with vascular 
infections were treated using rifampin-soaked Dacron 
grafts at our institution. For impregnation, the grafts 
were soaked in a saline solution containing 600rag 
rifampin (2mg/ml) at room temperature for at least 
15 rain before the implantation. Two patients had 
infected aortic aneurysms. One of them had a piece 
of a coronary catheter embedded into thrombus and 
aortic wall 3 years before. Because of suspected in- 
fection, a collagen-sealed graft (Hemashield; Meadox 
Medicals, Inc., Oakland, NJ, U.S.A.) was soaked with 
rifampin before the implantation. Cultures from the 
catheter, thrombus and aortic wall grew Staphylococcus 
epidermidis. ACT scan at 48 months showed no evi- 
dence of residual infection, and the patient did well 
after surgery. The other patient underwent emergency 
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treatment of a ruptured infrarenal aortic aneurysm 
using an in situ gelatin-sealed bifurcation graft (Uni- 
graft; B. Braun Melsungen AG, Melsungen, Germany) 
soaked with rifampin before the implantation. Cul- 
tures from thrombus and aortic wall grew Staphy- 
lococcus epidermidis and Enterococcus faecalis. The 
postoperative course was uneventful, but 6 months 
after surgery the patient presented with a left groin 
sinus and right groin abscess. CT scan showed re- 
current infection and perigraft collections. The pros- 
thesis was removed, and an axillofemoral PTFE graft 
was performed. The patient did well after surgery 
and has no evidence of infection 34 months after 
implantation of the extra-anatomic bypass. Two 
patients had locally infected grafts with groin abscesses 
and anastomotic false aneurysms. After debridement 
of the perigraft issue and local treatment with po- 
vidone-iodine (betadine), the infected prosthetic 
materials were removed. Two short 8ram Dacron 
grafts (one gelatin-sealed, the other collagen-sealed) 
soaked with rifampin were implanted in situ between 
the original Dacron prosthesis and the deep artery. 
Although routine microbiological cultures were neg- 
ative in one case, the other patient grew Staphylococcus 
epidermidis and Escherichia coli. Eight and 12 months 
later, recurrent groin infections occurred. One patient 
had an ocluded single limb that, after several extra- 
anatomic procedures and recurrent infections (Staphy- 
lococcus epidermidis, Pseudomona eruginosa, Acineto- 
bacter anitratus), required graft removal and amputa- 
tion. The other patien t was treated by unilateral graft 
limb removal without revascularisation which resulted 
in claudication only (Staphylococcus epidermidis and 
Escherichia coli). Finally, one patient was operated on 
for aortoenteric fistula. The aortofemoral bypass (end- 
to-side proximal anastomosis ) was removed, the aortic 
wall closed with patch plasty of endarterectomised 
femoral artery and a rifampin-soaked collagen axillo- 
bifemoral graft was performed. Culture of the excised 
graft grew Escherichia coli. After 5 months, the patient 
presented with groin abscess, and graft thrombosis 
without producing limb-threatening ischaemia. Angio- 
graphy showed good iliofemoral collateral circulation. 
Graft removal without revascularisation was decided 
after careful patch closure of femoral arteriotomies 
with autologous material. 
Contrary to previous reports, our results were not 
very encouraging: four redo surgery for recurrent 
infection, one amputation, and two patients with dis- 
abling claudication. To date, only one patient with in 
situ interposition graft of an infected aortic aneurysm 
remains asymptomatic. As a possible criticism, we 
admit that the concentration of rifampin in which 
grafts were immersed was low, although other authors 
have reported good results with the same doses. Given 
that the concentration f rifampin in which grafts are 
immersed seems to be the most important determinant 
of in vitro bioactivity, 4 we probably need a maximum 
concentration to reach a sufficient level to prevent 
prosthesis colonisation when they are used for in 
situreplacement of infected vascular grafts, However, 
caution is advised because resistance may develop. 9 
Likewise, cultures of material removed in our series 
generally showed polymicrobial association with 
Gram-negative bacilli. The best results with the use of 
rifampin-bonded vascular grafts, in the literature as 
well as in our experience, have been obtained in 
patients with bacterial infection of low virulence, i.e. 
Staphylococcus epidermidis or Staphylococcus aureus. 
However, despite the presence of infection, negative 
culture are frequently obtained and standard clinical 
practices for organism isolation do not usually allow 
an accurate microbiological diagnosis before graft re- 
moval. Intraoperative Gram staining is equally un- 
satisfactory, because it merely identities the presence 
of leukocytes, cocci or bacilli without specifying the 
species. In situ replacement byantibiotic bonded grafts 
may be a promising alternative in selected patients 
with a bacterial infection of low virulence when ex- 
cision and ex situ bypass are not feasible. 
J. A. Gonzalez-Fajardo, L. A. Carpintero and 
A. M. Mateo 
Valladolid, Spain 
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